What question did this study set out to answer?

This analysis aims to evaluate the cost-effectiveness of real-time continuous glucose monitoring (rt-CGM) compared to self-monitoring of blood glucose (SMBG) in type 2 diabetes patients.

March 12, 2026

Cost‐effectiveness analysis of Dexcom ONE + real‐time continuous glucose monitoring versus self‐monitoring of blood glucose in people with type 2 diabetes in Aotearoa New Zealand

Key Points

This analysis aims to evaluate the cost-effectiveness of real-time continuous glucose monitoring (rt-CGM) compared to self-monitoring of blood glucose (SMBG) in type 2 diabetes patients.
Cost-effectiveness analysis from payer perspective
Comparison between rt-CGM and SMBG
Assessment of complications and associated costs
RT-CGM shows a reduction in complications associated with type 2 diabetes
Cost reductions are linked to decreased risks of complications
Demonstrates potential for improved healthcare cost efficiency

Abstract

This analysis provides insight into the cost-effectiveness of rt-CGM versus SMBG from the perspective of payers in New Zealand, demonstrating reductions in the risks of complications in addition to reductions in their associated costs.

Bookmark

Cost‐effectiveness analysis of Dexcom ONE + real‐time continuous glucose monitoring versus self‐monitoring of blood glucose in people with type 2 diabetes in Aotearoa New Zealand

Key Points

Abstract

Cite This Study